Perspective Therapeutics Announces First Patient Dosed in
First patient with MC1R-positive metastatic melanoma treated with 212Pb-VMT01Preliminary data readout from dose escalation study expected Q4 2023 ...
Source: globenewswire.com
Page 3 - Markus Puhlmann News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Markus Puhlmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Markus Puhlmann Today - Breaking & Trending Today
Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma
First patient with MC1R-positive metastatic melanoma treated with 212Pb-VMT01Preliminary data readout from dose escalation study expected Q4 2023 RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 11, 2023 ... -August 11, 2023 at 08:06 am- MarketScreener
Source: marketscreener.com
Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates
VMT-α-NET for neuroendocrine cancers and VMT01 for melanoma are both entering therapeutic trials under IND at leading US institutions. First melanoma patient screened and imaged with... | June 21, 2023
Source: marketscreener.com
Viewpoint Molecular Targeting, Inc.: Viewpoint Molecular Targeting Announces Appointment of Markus Puhlmann, MD, MBA as Chief Medical Officer
Dr. Puhlmann has over 20 years of oncology drug development experience and has spearheaded the global development and approval of multiple cancer drugsCORALVILLE, IA / ACCESSWIRE / October 4, 2022 / Viewpoint
Source: finanznachrichten.de